Maybe I offend some now but:
Market jumps on RAC for an improvement of a 1980/90 Chemo that is pre-clinical and brags to have less side effects. Looking at their 1050 day survival chart they lost almost all patients due to breast cancer. Market drives MC above 200m.
Now comparing to IMU, about 3 times valued higher. So, either RAC is absolutely insanely overvalued or IMU insanely undervalued. One toxic chemo drug compared to 2 cutting edge technologies aiming at all cancer types with zero side effects.
Any comments?
Imugene's Leslie Chong says positive HER-Vaxx data 'validates entire platform', page-2
-
- There are more pages in this discussion • 163 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IMU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
4.6¢ |
Change
0.001(2.22%) |
Mkt cap ! $342.1M | |||
| Open | High | Low | Value | Volume |
| 4.5¢ | 4.7¢ | 4.5¢ | $906.2K | 19.67M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 20 | 9543864 | 4.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 4.6¢ | 1266571 | 1 |
View Market Depth
| Last trade - 16.10pm 08/11/2024 (20 minute delay) ? |
| IMU (ASX) Chart |